Arsenic trioxide sensitizes cancer stem cells to chemoradiotherapy. A new approach in the treatment of inoperable glioblastoma multiforme

Journal of B.U.ON.

Volumn 15, Issue 4, 2010, Pages 758-762

  Tomuleasa, Ciprian ^a,b   Soritau, O ^a   Kacso, G ^a,b   Fischer Fodor, E ^a   Cocis, A ^c   Ioani, H ^c   Timis, T ^b   Petrescu, M ^b   Cernea, D ^a   Virag, P ^a   Irimie, A ^a,b   Florian, I S ^b,c  

^a THE ONCOLOGY INSTITUTE PROF DR ION CHIRICUTA   (Romania)

^b IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^c Emergency University Clinical Hospital   (Romania)

Author keywords

Arsenic trioxide; Glioblastoma multiforme; In vitro model

Indexed keywords

ARSENIC TRIOXIDE; BEVACIZUMAB; CHEMOKINE RECEPTOR CXCR4; OCTAMER TRANSCRIPTION FACTOR 4; TEMOZOLOMIDE; TUMOR MARKER;

ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STEM CELL; CANCER THERAPY; CELL DIFFERENTIATION; CELL ISOLATION; CELL PROLIFERATION; DRUG ABSORPTION; DRUG EFFICACY; DRUG SENSITIVITY; EXPERIMENTAL ANIMAL; GLIOBLASTOMA; HUMAN; HUMAN CELL; IONIZING RADIATION; MESENCHYMAL STEM CELL; NEUROFILAMENT; POSTOPERATIVE CARE; POSTOPERATIVE PERIOD; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR BIOPSY; TUMOR CELL; UPREGULATION;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; ARSENICALS; BLOTTING, WESTERN; BRAIN NEOPLASMS; CELL PROLIFERATION; CELLS, CULTURED; COMBINED MODALITY THERAPY; DACARBAZINE; FEMALE; GLIAL FIBRILLARY ACIDIC PROTEIN; GLIOBLASTOMA; HUMANS; INTERMEDIATE FILAMENT PROTEINS; MESENCHYMAL STEM CELLS; NEOPLASTIC STEM CELLS; NERVE TISSUE PROTEINS; OCTAMER TRANSCRIPTION FACTOR-3; OXIDES; PLACENTA; PREGNANCY; RADIATION TOLERANCE; RADIATION, IONIZING; RADIATION-SENSITIZING AGENTS; RECEPTORS, CXCR4; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 78651390005     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-996.
2. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med 2008; 359: 492-507.
3. Yan H, Bigner DD, Velculescu V, Parsons DW. Mutant metabolic enzymes are at the origin of gliomas. Cancer Res 2009; 69: 9157-9159.
4. Tomuleasa C, Soritau O, Rus-Ciuca D et al. Functional and molecular characterization of glioblastoma multiforme derived cancer stem cells. J BUON 2010 (in press).
5. Clarke MF, Dick JE, Dirks PB et al. Cancer stem cells- perspectives on current status and future directions: AACR workshop on cancer stem cells. Cancer Res 2006; 66: 9339-9344.
6. Ito K, Bernardi R, Morotti A et al. PML targeting eradicates quiescent leukaemia-initiating cells. Nature 2008; 453: 1072-1078.
7. Kobayashi Y, Hatta Y, Ishizuka H et al. Successful post-remission therapy with a combination of all-trans retinoic acid and arsenic trioxide in an elderly Japanese patient newly diagnosed with acute promyelocytic leukemia. Int J Hematol 2010; 91: 152-153.
8. de Thé H, Chelbi-Alix MK. APL, a model disease for cancer therapies? Oncogene 2001; 20: 7136-7139.
9. Nieder C, Mehta MP, Jalali R. Combined radio- and chemotherapy of brain tumours in adult patients. Clin Oncol 2009; 21: 515-524.
10. Marosi C. Chemotherapy for malignant gliomas. Wien Med Wochenschr 2006; 156: 346-350.
11. Mihu CM, Rus-Ciuca D, Soritau O, Susman S, Mihu D. Isolation and characterization of mesenchymal stem cells from the amniotic membrane. Rom J Morphol Embryol 2009; 50: 73-77.
12. Tomuleasa C, Soritau O, Rus-Ciuca D et al. Isolation and characterization of hepatic cancer cells with stem like properties from hepatocellular carcinoma. J Gastrointestin Liv Dis 2010; 19: 61-67.
13. Blumenthal DT, Won M, Mehta MP et al. Short delay in initiation of radiotherapy may not affect outcome of patients with glioblastoma: a secondary analysis from the Radiation Therapy Oncology Groups database. J Clin Oncol 2009; 27: 733-739.
14. Stupp R, Mason WP, van den Bent MJ et al. European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-996.
15. Taphoom MJ, Stupp R, Coens C et al. European Organisation for Research and Treatment of Cancer Brain Tumor Group; EORTC Radiotherapy Group; National Cancer Institute of Canada Clinical Trials Group. Health-related quality of life in patients with glioblastoma: a randomised controlled trial. Lancet Oncol 2005; 6: 937-944.
16. Cohnheim J. Uber Entzündung und Eiterung. Virchows Arch 1867; 40: 1-79.
17. Woodward WA, Bristow RG, Clarke MF et al. Radiation Therapy Oncology Group translational research program stem cell symposium: incorporating stem cell hypotheses into clinical trials. Int J Radiat Oncol Biol Phys 2009; 74: 1580-1591.
18. Estey E, Garcia-Manero G, Farrajoli A et al. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood 2006; 107: 3469-3473.
19. Miller WH Jr. Molecular targets of arsenic trioxide in malignant cells. The Oncologist 2002; 7 (Suppl 1): 14-19.
20. Fojo T, Bates S. Arsenic trioxide (As(2)O(3)): still a mystery. Cell Cycle 2002; 1: 183-186.
21. Akay C, Thomas C 3rd, Gazitt Y. Arsenic trioxide and paclitaxel induce apoptosis by different mechanisms. Cell Cycle 2004; 3: 324-334.
22. Ning S, Knox SJ. Increased cure rate of glioblastoma using concurrent therapy with radiotherapy and arsenic trioxide. Int J Radiat Oncol Biol Phys 2004; 60: 197-203.
23. Docampo R, Moreno SNJ. Current chemotherapy of human African trypanosomiasis. Parasitol Res 2003; 90: S10-S13.